New hope for head and neck cancer patients who Can't take chemo
NCT ID NCT07445048
First seen Mar 05, 2026 · Last updated Apr 28, 2026 · Updated 7 times
Summary
This phase 3 trial tests a new treatment for high-risk head and neck cancer patients who cannot receive the standard chemotherapy drug cisplatin. After surgery, patients get radiation therapy combined with nimotuzumab (a targeted drug) followed by benmelstobart (an immunotherapy). The goal is to see if this approach improves disease-free survival compared to standard care. About 370 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai 9th people's hospital
RECRUITINGShanghai, 200011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.